vs
Side-by-side financial comparison of CHIMERA INVESTMENT CORP (CIM) and STEM, INC. (STEM). Click either name above to swap in a different company.
CHIMERA INVESTMENT CORP is the larger business by last-quarter revenue ($66.2M vs $47.1M, roughly 1.4× STEM, INC.). CHIMERA INVESTMENT CORP runs the higher net margin — 42.8% vs -33.9%, a 76.7% gap on every dollar of revenue. On growth, CHIMERA INVESTMENT CORP posted the faster year-over-year revenue change (0.5% vs -15.6%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs 0.8%).
Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
CIM vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.2M | $47.1M |
| Net Profit | $28.3M | $-16.0M |
| Gross Margin | — | 48.9% |
| Operating Margin | 42.6% | -17.7% |
| Net Margin | 42.8% | -33.9% |
| Revenue YoY | 0.5% | -15.6% |
| Net Profit YoY | 119.3% | 68.8% |
| EPS (diluted) | $0.05 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $66.2M | $47.1M | ||
| Q3 25 | $65.0M | $38.2M | ||
| Q2 25 | $66.0M | $38.4M | ||
| Q1 25 | $69.2M | $32.5M | ||
| Q4 24 | $65.8M | $55.8M | ||
| Q3 24 | $66.5M | $29.3M | ||
| Q2 24 | $67.3M | $34.0M | ||
| Q1 24 | $65.1M | $25.5M |
| Q4 25 | $28.3M | $-16.0M | ||
| Q3 25 | $-580.0K | $-23.8M | ||
| Q2 25 | $35.5M | $202.5M | ||
| Q1 25 | $167.3M | $-25.0M | ||
| Q4 24 | $-146.5M | $-51.1M | ||
| Q3 24 | $136.5M | $-148.3M | ||
| Q2 24 | $56.7M | $-582.3M | ||
| Q1 24 | $129.5M | $-72.3M |
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | -95.0% |
| Q4 25 | 42.6% | -17.7% | ||
| Q3 25 | -0.5% | -33.6% | ||
| Q2 25 | 54.3% | -34.8% | ||
| Q1 25 | — | -65.0% | ||
| Q4 24 | -222.6% | -84.4% | ||
| Q3 24 | — | -493.2% | ||
| Q2 24 | 84.2% | -1705.5% | ||
| Q1 24 | — | -267.0% |
| Q4 25 | 42.8% | -33.9% | ||
| Q3 25 | -0.9% | -62.2% | ||
| Q2 25 | 53.7% | 527.8% | ||
| Q1 25 | 241.7% | -76.9% | ||
| Q4 24 | -222.6% | -91.6% | ||
| Q3 24 | 205.4% | -506.3% | ||
| Q2 24 | 84.2% | -1712.6% | ||
| Q1 24 | 198.8% | -283.9% |
| Q4 25 | $0.05 | $-4.40 | ||
| Q3 25 | $-0.27 | $-2.84 | ||
| Q2 25 | $0.17 | $-1.79 | ||
| Q1 25 | $1.77 | $-0.15 | ||
| Q4 24 | $-2.06 | $-15.29 | ||
| Q3 24 | $1.39 | $-18.24 | ||
| Q2 24 | $0.41 | $-71.81 | ||
| Q1 24 | $1.36 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $278.6M | $48.9M |
| Total DebtLower is stronger | $251.5M | — |
| Stockholders' EquityBook value | $2.6B | $-249.4M |
| Total Assets | $15.8B | $308.9M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.6M | $48.9M | ||
| Q3 25 | $491.5M | $43.1M | ||
| Q2 25 | $250.2M | $40.8M | ||
| Q1 25 | $253.3M | $58.6M | ||
| Q4 24 | $84.0M | $56.3M | ||
| Q3 24 | $97.3M | $75.4M | ||
| Q2 24 | $162.3M | $89.6M | ||
| Q1 24 | $169.0M | $112.8M |
| Q4 25 | $251.5M | — | ||
| Q3 25 | $251.0M | — | ||
| Q2 25 | $135.2M | — | ||
| Q1 25 | $134.9M | — | ||
| Q4 24 | $134.6M | — | ||
| Q3 24 | $134.4M | — | ||
| Q2 24 | $62.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.6B | $-249.4M | ||
| Q3 25 | $2.6B | $-235.7M | ||
| Q2 25 | $2.6B | $-214.1M | ||
| Q1 25 | $2.6B | $-417.5M | ||
| Q4 24 | $2.5B | $-398.4M | ||
| Q3 24 | $2.7B | $-344.1M | ||
| Q2 24 | $2.6B | $-203.2M | ||
| Q1 24 | $2.6B | $371.6M |
| Q4 25 | $15.8B | $308.9M | ||
| Q3 25 | $15.1B | $362.6M | ||
| Q2 25 | $14.9B | $379.2M | ||
| Q1 25 | $13.2B | $405.1M | ||
| Q4 24 | $13.1B | $437.4M | ||
| Q3 24 | $13.7B | $537.8M | ||
| Q2 24 | $13.1B | $691.5M | ||
| Q1 24 | $12.5B | $1.3B |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-248.9M | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -8.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-248.9M | $8.2M | ||
| Q3 25 | $-137.5M | $11.4M | ||
| Q2 25 | $-7.4M | $-21.3M | ||
| Q1 25 | $48.8M | $8.5M | ||
| Q4 24 | $205.7M | $-14.7M | ||
| Q3 24 | $41.4M | $-9.4M | ||
| Q2 24 | $69.0M | $-11.9M | ||
| Q1 24 | $57.3M | $-621.0K |
| Q4 25 | -8.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.21× | -0.11× | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
